Primary cell cultures as models of prostate cancer development

Endocrine-Related Cancer

Volumn 12, Issue 1, 2005, Pages 19-47

  Peehl, D M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYL ISOTHIOCYANATE; APIGENIN; BIOCHANIN A; BOWMAN BIRK INHIBITOR; CELL MARKER; CYTOTOXIN; DAIDZEIN; FLAVONOID; GEFITINIB; GENISTEIN; LYCOPENE; MEMBRANE ANTIGEN; MEMBRANE METALLOENDOPEPTIDASE; QUERCETIN; QUINAZOLINE DERIVATIVE; RETINOID; SELENIUM; SOMATOSTATIN; STEROID HORMONE; VITAMIN D;

ADENOCARCINOMA; ANGIOGENESIS; APOPTOSIS; BASAL CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL ADHESION; CELL CULTURE; CELL DIFFERENTIATION; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CYTOGENETICS; EPITHELIUM CELL; GENE EXPRESSION; GENE THERAPY; HORMONE METABOLISM; HUMAN; HUMAN CELL; IMAGING; NEUROSECRETORY CELL; PHENOTYPE; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SECRETORY CELL; SENESCENCE; STEM CELL;

ADENOCARCINOMA; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TUMOR STEM CELLS;

EID: 16444386240     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00795     Document Type: Review

References (230)

1. Abdul M & Hoosein N 2000 Changes in beta-2 microglobulin expression in prostate cancer. Urologic Oncology 5 168-172.
2. Abrahamsson PA 1999 Neuroendocrine differentiation in prostatic carcinoma. Prostate 39 135-148.
3. Ackerstaff E, Pflug BR, Nelson JB & Bhujwalla ZM 2001 Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Research 61 3599-3603.
4. Adam RM, Borer JG, Williams J, Eastham JA, Loughlin KR & Freeman MR 1999 Amphiregulin is coordinately expressed with heparin-binding epidermal growth factor-like growth factor in the interstitial smooth muscle of the human prostate. Endocrinology 140 5866-5875.
5. Adams J, Palombella VJ & Elliott PJ 2000 Proteasome inhibition: a new strategy in cancer treatment. Investigational New Drugs 18 109-121.
6. Asgari K, Sesterhenn IA, McLeod DG, Cowan K, Moul JW, Seth P & Srivastava S 1997 Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. International Journal of Cancer 71 377-382.
7. Balint EE & Vousden KH 2001 Activation and activities of the p53 tumour suppressor protein. British Journal of Cancer 85 1813-1823.
8. Belair CD, Yeager TR, Lopez PM & Reznikoff CA 1997 Telomerase activity: a biomarker of cell proliferation, not malignant transformation. PNAS 94 13677-13682.
9. Benning CM & Kyprianou N 2002 Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha 1-adrenoceptor-independent action. Cancer Research 62 597-602.
10. Berges RR, Vukanovic J, Epstein JI, Carmichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC & Isaacs JT 1995 Implication of cell kinetic changes during the progression of human prostatic cancer. Clinical Cancer Research 1 473-480.
11. Berns A 2002 Senescence: a companion in chemotherapy? Cancer Cell 1 309-311.
12. Berthaut I, Portois MC, Cussenot O & Mowszowicz I 1996 Human prostatic cells in culture: different testosterone metabolic profile in epithelial cells and fibroblasts from normal or hyperplastic prostates. Journal of Steroid Biochemistry and Molecular Biology 58 235-242.
13. Bettendorf O, Heine B, Kneif S, Eltze E, Semjonow A, Herbst H, Stein H, Bocker W & Poremba C 2003 Expression-patterns of the RNA component (hTR) and the catalytic subunit (hTERT) of human telomerase in nonneoplastic prostate tissue, prostatic intraepithelial neoplasia, and prostate cancer. Prostate 55 99-104.
14. Bonkhoff H 1998 Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate. Supplement 8 18-22.
15. Bonkhoff H, Stein U & Remberger K 1994 Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Human Pathology 25 42-46.
16. Bosland MC, Chung LWK, Greenberg NM, Ho S, Isaacs JT, Lane K, Peehl DM, Thompson TC, van Steenbrugge GJ & van Weerden WM 1996 Recent advances in the development of animal and cell culture models for prostatic cancer research. Urologic Oncology 2 99-128.
17. Bostwick DG, Pacelli A & Lopez-Beltran A 1996 Molecular biology of prostatic intraepithelial neoplasia. Prostate 29 117-134.
18. Brawer MK, Peehl DM, Stamey TA & Bostwick DG 1985 Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Research 45 3663-3667.
19. Brawer MK, Bostwick DG, Peehl DM & Stamey TA 1986 Keratin protein in human prostatic tissue and cell culture. Annals of the New York Academy of Sciences 455 729-731.
20. Bromfield GP, Meng A, Warde P & Bristow RG 2003 Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer and Prostatic Disease 6 73-85.
21. Brothman AR, Maxwell TM, Cui J, Deubler DA & Zhu XL 1999 Chromosomal clues to the development of prostate tumors. Prostate 38 303-312.
22. Bull JH, Ellison G, Patel A, Muir G, Walker M, Underwood M, Khan F & Paskins L 2001 Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. British Journal of Cancer 84 1512-1519.
23. Burroughs KD, Oh J, Barrett JC & DiAugustine RP 2003 Phosphatidylinositol 3-kinase and MEK1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1? Molecular Cancer Research 1 312-322.
24. Byrne RL, Leung H & Neal DE 1996 Peptide growth factors in the prostate as mediators of stromal epithelial interaction. British Journal of Urology 77 627-633.
25. Campbell CL, Savarese DM, Quesenberry PJ & Savarese TM 1999 Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: predominance of vascular endothelial growth factor. International Journal of Cancer 80 868-874.
26. Castro P, Giri D, Lamb D & Ittmann M 2003 Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 55 30-38.
27. Castro P, Xia C, Gomez L, Lamb DJ & Ittmann M 2004 Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 60 153-159.
28. Chatterjee S, Brite KH & Matsumura A 2001 Induction of apoptosis of integrin-expressing human prostate cancer cells by cyclic Arg-Gly-Asp peptides. Clinical Cancer Research 1 3006-3011.
29. Chen LM, Zhang X & Chai KX 2004 Regulation of prostasin expression and function in the prostate. Prostate 59 1-12.
30. Chen Z, Fan Z, McNeal JE, Nolley R, Caldwell MC, Mahadevappa M, Zhang Z, Warrington JA & Stamey TA 2003 Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. Journal of Urology 169 1316-1319.
31. Chetcuti A, Margan SH, Russell P, Mann S, Millar DS, Clark SJ, Rogers J, Handelsman DJ & Dong Q 2001 Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Research 61 6331-6334.
32. Choi J, Shendrik I, Peacocke M, Peehl D, Buttyan R, Ikeguchi EF, Katz AE & Benson MC 2000 Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. Urology 56 160-166.
33. Chopra DP, Grignon DJ, Joiakim A, Mathieu PA, Mohamed A, Sakr WA, Powell IJ & Sarkar FH 1996 Differential growth factor responses of epithelial cell cultures derived from normal human prostate, benign prostatic hyperplasia, and primary prostate carcinoma. Journal of Cellular Physiology 169 269-280.
34. Chopra DP, Menard RE, Januszewski J & Mattingly RR 2004 TNF-alpha-mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. Cancer Letters 203 145-154.
35. Coffey RN, Watson RW, Hegarty PK, Watson CL, Wolohan L, Brady HR, O'Keane C & Fitzpatrick JM 2001 Priming prostate carcinoma cells for increased apoptosis is associated with up-regulation of the caspases. Cancer 92 2297-2308.
36. Cohen P, Peehl DM, Stanley TA, Wilson KF, Clemmons DR & Rosenfeld RG 1993 Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. Journal of Clinical Endocrinology and Metabolism 76 1031-1035.
37. Collins AT, Habib FK, Maitland NJ & Neal DE 2001 Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)- integrin expression. Journal of Cell Science 114 3865-3872.
38. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G & Klocker H 1996 Regulation of prostatic growth and function by peptide growth factors. Prostate 28 392-405.
39. Cussenot O, Berthon P, Cochand-Priollet B, Maitland NJ & Le Due A 1994 Immunocytochemical comparison of cultured normal epithelial prostatic cells with prostatic tissue sections. Experimental Cell Research 214 83-92.
40. Das R, Hammamieh R, Neill R, Melhem M & Jett M 2001 Expression pattern of fatty acid-binding proteins in human normal and cancer prostate cells and tissues. Clinical Cancer Research 7 1706-1715.
41. Davila M, Frost AR, Grizzle WE & Chakrabarti R 2003 LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: implications in prostate cancer. Journal of Biological Chemistry 278 36868-36875.
42. Davis LD, Zhang W, Merseburger A, Young D, Xu L, Rhim JS, Moul JW, Srivastava S & Sesterhenn IA 2002 p63 expression profile in normal and malignant prostate epithelial cells. Anticancer Research 22 3819-3825.
43. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB & Nelson WG 2004 Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. Journal of Cellular Biochemistry 91 459-477.
44. Delos S, Carsol JL, Fina F, Raynaud JP & Martin PM 1998 5 alpha-reductase and 17 beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate. International Journal of Cancer 75 840-846.
45. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA & Chinnaiyan AM 2001 Delineation of prognostic biomarkers in prostate cancer. Nature 412 822-826.
46. Djakiew D 2000 Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 42 150-160.
47. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC & Bouck NP 2001 Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 49 293-305.
48. Downing SR, Jackson P & Russell PJ 2001 Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression, a review of the evidence. Urologic Oncology 6 103-110.
49. Dumble ML, Knight B, Quail EA & Yeoh GC 2001 Hepatoblast-like cells populate the adult p53 knockout mouse liver: evidence for a hyperproliferative maturation-arrested stem cell compartment. Cell Growth and Differentiation 12 223-231.
50. Dunlap N, Schwartz GG, Eads D, Cramer SD, Sherk AB, John V & Koumenis C 2003 1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha, 25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. British Journal of Cancer 89 746-753.
51. El-Alfy M, Luu-The V, Huang XF, Berger L, Labrie F & Pelletier G 1999 Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology 140 1481-1491.
52. Etminan M, Takkouche B & Caamano-Isorna F 2004 The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiology, Biomarkers and Prevention 13 340-345.
53. Ficazzola MA, Fraiman M, Gitlin J, Woo K, Melamed J, Rubin MA & Walden PD 2001 Antiproliferative B cell translocation gene 2 protein is down-regulated posttranscriptionally as an early event in prostate carcinogenesis. Carcinogenesis 22 1271-1279.
54. Flatt PM, Price JO, Shaw A & Pietenpol JA 1998 Differential cell cycle checkpoint response in normal human keratinocytes and fibroblasts. Cell Growth and Differentiation 9 535-543.
55. Fong CJ, Sherwood ER, Sutkowski DM, Abu-Jawdeh GM, Yokoo H, Bauer KD, Kozlowski JM & Lee C 1991 Reconstituted basement membrane promotes morphological and functional differentiation of primary human prostatic epithelial cells. Prostate 19 221-235.
56. Gao J, Arnold JT & Isaacs JT 2001 Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Research 61 5038-5044.
57. Garraway LA, Lin D, Signoretti S, Waltregny D, Dilks J, Bhattacharya N & Loda M 2003 Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate 55 206-218.
58. Ghosh J 2004 Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochemical and Biophysical Research Communications 315 624-635.
59. Gingras S & Simard J 1999 Induction of Sbeta-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines. Endocrinology 140 4573-4584.
60. Giri D, Ozen M & Ittmann M 2001 Interleukin-6 is an autocrine growth factor in human prostate cancer. American Journal of Pathology 159 2159-2165.
61. Girinsky T, Koumenis C, Graeber TG, Peehl DM & Giaccia AJ 1995 Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Research 55 3726-3731.
62. Glinsky GV, Krones-Herzig A, Glinskii AB & Gebauer G 2003 Microarray analysis of xenograft-derived cancer cell lines representing multiple experimental models of human prostate cancer. Molecular Carcinogenesis 37 209-221.
63. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM & Gerald WL 2004 Gene expression profiling predicts clinical outcome of prostate cancer. Journal of Clinical Investigation 113 913-923.
64. Gommersall LM, Khanim FL, Peehl DM, Doherty AH & Campbell MJ 2004 Epigenetic repression of transcription by the vitamin D(3) receptor in prostate cancer cells. Journal of Steroid Biochemistry and Molecular Biology 89-90 251-256.
65. Goossens K, Deboel L, Swinnen JV, Roskams T, Manin M, Rombauts W & Verhoeven G 2002 Both retinoids and androgens are required to maintain or promote functional differentiation in reaggregation cultures of human prostate epithelial cells. Prostate 53 34-49.
66. Grant ES, Batchelor KW & Habib FK 1996 Androgen independence of primary epithelial cultures of the prostate is associated with a down-regulation of androgen receptor gene expression. Prostate 29 339-349.
67. Guo X, Knudsen BS, Peehl DM, Ruiz A, Bok D, Rando RR, Rhim JS, Nanus DM & Gudas LJ 2002 Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer Research 62 1654-1661.
68. Gupta S, Afaq F & Mukhtar H 2001 Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochemical and Biophysical Research Communications 287 914-920.
69. Hall JA, Maitland NJ, Stower M & Lang SH 2002 Primary prostate stromal cells modulate the morphology and migration of primary prostate epithelial cells in type 1 collagen gels. Cancer Research 62 58-62.
70. Hammond LA, Van Krinks CH, Durham J, Tomkins SE, Burnett RD, Jones EL, Chandraratna RA & Brown G 2001 Antagonists of retinoic acid receptors (RARs) are potent growth inhibitors of prostate carcinoma cells. British Journal of Cancer 85 453-462.
71. Han EK, Lim JT, Arber N, Rubin MA, Xing WQ & Weinstein IB 1998 Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 35 95-101.
72. Hart CA, Scott LJ, Bagley S, Bryden AA, Clarke NW & Lang SH 2002 Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. British Journal of Cancer 86 1136-1142.
73. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D & Cunha GR 2001 Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Research 61 8135-8142.
74. He XY, Yang YZ, Peehl DM, Lauderdale A, Schulz H & Yang SY 2003 Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase. Journal of Steroid Biochemistry and Molecular Biology 87 191-198.
75. Hedlund TE, Johannes WU & Miller GJ 2003 Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 54 68-78.
76. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Klocker H, Bartsch G & Culig Z 2000 Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. Journal of Pathology 191 239-244.
77. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM & Chen CS 2000 The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. Journal of Biological Chemistry 275 11397-11403.
78. Hudson DL, O'Hare M, Watt FM & Masters JR 2000 Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells. Laboratory Investigation 80 1243-1250.
79. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT & Day ML 1995 Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. American Journal of Pathology 147 386-396.
80. Husain SR, Kawakami K, Kawakami M & Puri RK 2003 Interleukin-4 receptor-targeted cytotoxin therapy of androgen-dependent and -independent prostate carcinoma in xenograft models. Molecular Cancer Therapeutics 2 245-254.
81. Ide H, Seligson DB, Memarzadeh S, Xin L, Horvath S, Dubey P, Flick MB, Kacinski BM, Palotie A & Witte ON 2002 Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. PNAS 99 14404-14409.
82. Isaacs JT 2000 Apoptosis: translating theory to therapy for prostate cancer. Journal of the National Cancer Institute 92 1367-1369.
83. Ittman M & Mansukhani A 1997 Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. Journal of Urology 157 351-356.
84. Iype PT, Iype LE, Verma M & Kaighn ME 1998 Establishment and characterization of immortalized human cell lines from prostatic carcinoma and benign prostatic hyperplasia. International Journal of Oncology 12 257-263.
85. Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, Smith JA Jr & Shappell SB 2000 Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Human Pathology 31 1146-1154.
86. Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB & Nassif N 1998 Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Research 58 5310-5314.
87. Kanagawa K, Sugimura K, Kuratsukuri K, Ikemoto S, Kishimoto T & Nakatani T 2003 Norepinephrine activates P44 and P42 MAPK in human prostate stromal and smooth muscle cells but not in epithelial cells. Prostate 56 313-318.
88. Kennedy AR & Wan XS 2002 Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells. Prostate 50 125-133.
89. Kim SJ, Johnson M, Koterba K, Herynk MH, Uehara H & Gallick GE 2003 Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clinical Cancer Research 9 5161-5170.
90. Kiviharju TM, Lecane PS, Sellers RG & Peehl DM 2002 Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clinical Cancer Research 8 2666-2674.
91. Klein RD & Fischer SM 2002 Black tea polyphenols inhibit IGF-I-induced signaling through Akt in normal prostate epithelial cells and Dul45 prostate carcinoma cells. Carcinogenesis 23 217-221.
92. Klein RD, Maliner-Jongewaard MS, Udayakumar TS, Boyd JL, Nagle RB & Bowden GT 1999 Promatrilysin expression is induced by fibroblast growth factors in the prostatic carcinoma cell line LNCaP but not in normal primary prostate epithelial cells. Prostate 41 215-223.
93. Koeffler HP 2003 Peroxisome proliferator-activated receptor gamma and cancers. Clinical Cancer Research 9 1-9.
94. Kooistra A, Elissen NM, Konig JJ, Vermey M, van der Kwast TH, Romijn JC & Schroder FH 1995 Immunocytochemical characterization of explant cultures of human prostatic stromal cells. Prostate 27 42-49.
95. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA & Smithies O 1998 Generation and reproductive phenotypes of mice lacking estrogen receptor beta. PNAS 95 15677-15682.
96. Krishnan AV, Peehl DM & Feldman D 2003 Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. Journal of Cellular Biochemistry 88 363-371.
97. Kyprianou N, Tu H & Jacobs SC 1996 Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Human Pathology 27 668-675.
98. Lang SH, Clarke NW, George NJ, Allen TD & Testa NG 1998 Interaction of prostate epithelial cells from benign and malignant tumor tissue with bone-marrow stroma. Prostate 34 203-213.
99. Lang SH, Stark M, Collins A, Paul AB, Stower MJ & Maitland NJ 2001 Experimental prostate epithelial morphogenesis in response to stroma and three-dimensional matrigel culture. Cell Growth and Differentiation 12 631-640.
100. Lau KM, LaSpina M, Long J & Ho SM 2000 Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Research 60 3175-3182.
101. Leav I, McNeal JE, Kwan PW, Komminoth P & Merk FB 1996 Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: an immunohistochemical and in situ hybridization study. Prostate 29 137-145.
102. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H & Ho SM 2001 Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. American Journal of Pathology 159 79-92.
103. Lebedeva IV, Sarkar D, Su ZZ, Kitada S, Dent P, Stein CA, Reed JC & Fisher PB 2003 Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 22 8758-8773.
104. Lecane PS, Kiviharju TM, Sellers RG & Peehl DM 2003 Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line. Prostate 54 258-267.
105. Lee KL & Peehl DM 2004 Molecular and cellular pathogenesis of benign prostatic hyperplasia. Journal of Urology 172 1784-1791.
106. Lee SW, Reimer CL, Fang L, Iruela-Arispe ML & Aaronson SA 2000 Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression. Molecular and Cellular Biology 20 1723-1732.
107. Lewis KC & Hochadel JF 1999 Retinoid metabolism in the prostate: effects of administration of the synthetic retinoid N-(4-hydroxyphenyl) retinamide. Cancer Research 59 5947-5955.
108. Lim JT, Piazza GA, Man EK, Delohery TM, Li H, Finn TS, Buttyan R, Yamamoto H, Sperl GJ, Brendel K et al. 1999 Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochemical Pharmacology 58 1097-1107.
109. Lin XS, Denmeade SR, Cisek L & Isaacs JT 1997 Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. Prostate 33 201-207.
110. Liu AY 2000 Differential expression of cell surface molecules in prostate cancer cells. Cancer Research 60 3429-3434.
111. Liu AY & Peehl DM 2001 Characterization of cultured human prostatic epithelial cells by cluster designation antigen expression. Cell and Tissue Research 305 389-397.
112. Liu AY & True LD 2002 Characterization of prostate cell types by CD cell surface molecules. American Journal of Pathology 160 37-43.
113. Liu AY, Corey E, Vessella RL, Lange PH, True LD, Huang GM, Nelson PS & Hood L 1997a Identification of differentially expressed prostate genes: increased expression of transcription factor ETS-2 in prostate cancer. Prostate 30 145-153.
114. Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL, Lange PH, Hood L & van den Engh G 1997b Cell-cell interaction in prostate gene regulation and cytodifferentiation. PNAS 94 10705-10710.
115. Liu AY, Nelson PS, van den Engh G & Hood L 2002 Human prostate epithelial cell-type cDNA libraries and prostate expression patterns. Prostate 50 92-103.
116. Liu JW, Shen JJ, Tanzillo-Swarts A, Bhatia B, Maldonado CM, Person MD, Lau SS & Tang DG 2003 Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 22 1475-1485.
117. Lokeshwar VB, Rubinowicz D, Schroeder GL, Forgacs E, Minna JD, Block NL, Nadji M & Lokeshwar BL 2001 Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. Journal of Biological Chemistry 276 11922-11932.
118. Mahmud S, Franco E & Aprikian A 2004 Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. British Journal of Cancer 90 93-99.
119. Marinese D, Patel R & Waiden PD 2003 Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate 54 230-237.
120. Maroni PD, Koul S, Meacham RB & Koul HK 2004 Mitogen activated protein kinase signal transduction pathways in the prostate. Cell Communication and Signaling 2 5.
121. Martikainen P, Kyprianou N & Isaacs JT 1990 Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology 127 2963-2968.
122. McKeon F 2004 p63 and the epithelial stem cell: more than status quo? Genes and Development 18 465-469.
123. McNeal JE 1988 Significance of duct-acinar dysplasia in prostatic carcinogenesis. Prostate 13 91-102.
124. McNeal JE, Villers A, Redwine EA, Freiha FS & Stamey TA 1991 Microcarcinoma in the prostate: its association with duct-acinar dysplasia. Human Pathology 22 644-652.
125. McNeal JE, Haillot O & Yemoto C 1995 Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. Prostate 27 258-268.
126. Merchant DJ 1990 Primary expiant culture of human prostate tissue: a model for the study of prostate physiology and pathology. Prostate 16 103-126.
127. Meyer KM, Hess SM, Tlsty TD & Leadon SA 1999 Human mammary epithelial cells exhibit a differential p53-mediated response following exposure to ionizing radiation or UV light. Oncogene 18 5795-5805.
128. Michalaki V, Syrigos K, Charles P & Waxman J 2004 Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. British Journal of Cancer 90 2312-2316.
129. Miniati DN, Chang Y, Shu WP, Peehl DM & Liu BC 1996 Role of prostatic basal cells in the regulation and suppression of human prostate cancer cells. Cancer Letters 104 137-144.
130. Mitchen J, Oberley T & Wilding G 1997 Extended culturing of androgen-responsive human primary epithelial prostate cell isolates by continuous treatment with interstitial collagenase. Prostate 30 7-19.
131. Moore MG, Wetterau LA, Francis MJ, Peehl DM & Cohen P 2003 Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. International Journal of Cancer 105 14-19.
132. Nelson PS, Plymate SR, Wang K, True LD, Ware JL, Gan L, Liu AY & Hood L 1998 Kevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. Cancer Research 58 232-236.
133. Nesterov A, Ivashchenko Y & Kraft AS 2002 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 21 1135-1140.
134. Nie D, Che M, Zacharek A, Qiao Y, Li L, Li X, Lamberti M, Tang K, Cai Y, Guo Y et al. 2004 Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. American Journal of Pathology 164 429-439.
135. Nojima D, Li LC, Dharia A, Perinchery G, Ribeiro-Filho L, Yen TS & Dahiya R 2001 CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma. Cancer 92 2076-2083.
136. Obermuller-Jevic UC, Olano-Martin E, Corbacho AM, Eiserich JP, van der Vliet A, Valacchi G, Cross CE & Packer L 2003 Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. Journal of Nutrition 133 3356-3360.
137. Pakneshan P, Xing RH & Rabbani SA 2003 Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB Journal 17 1081-1088.
138. Pantel K, Dickmanns A, Zippelius A, Klein C, Shi J, Hoechtlen-Vollmar W, Schlimok G, Weckermann D, Oberneder R, Fanning E et al. 1995 Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. Journal of the National Cancer Institute 87 1162-1168.
139. Paris PL, Albertson DG, Alers JC, Andaya A, Carroll P, Fridlyand J, Jain AN, Kamkar S, Kowbel D, Krijtenburg PJ et al. 2003 High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. American Journal of Pathology 162 763-770.
140. Pasquali D, Rossi V, Esposito D, Abbondanza C, Puca GA, Bellastella A & Sinisi AA 2001 Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. Journal of Clinical Endocrinology and Metabolism 86 2051-2055.
141. Patel S, Turner PR, Stubberfield C, Barry E, Rohlff CR, Stamps A, McKenzie E, Young K, Tyson K, Terrett J et al. 2002 Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer. International Journal of Cancer 97 416-424.
142. Peehl DM 1996 Cellular biology of prostatic growth factors. Prostate. Supplement 6 74-78.
143. Peehl DM 2004 Are primary cultures realistic models of prostate cancer? Journal of Cellular Biochemistry 91 185-195.
144. Peehl DM & Feldman D 2003 The role of vitamin D and retinoids in controlling prostate cancer progression. Endocrine-Related Cancer 10 131-140.
145. Peehl DM & Rubin JS 1995 Keratinocyte growth factor: an androgen-regulated mediator of stromal-epithelial interactions in the prostate. World Journal of Urology 13 312-317.
146. Peehl DM & Sellers RG 2002 Epithelial cell culture: prostate. In Methods of Tissue Engineering, pp 247-261. Eds A Atala & R Lanza. San Diego, CA: Academic Press.
147. Peehl DM, Wong ST, Bazinet M & Stamey TA 1989 In vitro studies of human prostatic epithelial cells: attempts to identify distinguishing features of malignant cells. Growth Factors 1 237-250.
148. Peehl DM, Wong ST & Stamey TA 1993 Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate 23 69-78.
149. Peehl DM, Erickson E, Malspeis L, Mayo J, Camalier RF, Monks A, Cronise P, Paull K & Grever MR 1994a In vitro prostate cancer drug screen. In Fundamental Approaches to the Diagnosis and Treatment of Prostate Cancer and BPH, pp 57-71. Eds K Imai, J Shimazaki & JP Karr. New York: Academic Press.
150. Peehl DM, Leung GK & Wong ST 1994b Keratin expression: a measure of phenotypic modulation of human prostatic epithelial cells by growth inhibitory factors. Cell and Tissue Research 277 11-18.
151. 3 on prostatic epithelial cells. Urologic Oncology 1 188-294.
152. Peehl DM, Sellers RG & McNeal JE 1996 Keratin 19 in the adult human prostate: tissue and cell culture studies. Cell and Tissue Research 285 171-176.
153. Peehl DM, Seto E, Hsu JY & Feldman D 2002 Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. Journal of Urology 168 1583-1588.
154. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC & Chung LW 1995 c-Met proto-oncogene expression in benign and malignant human prostate tissues. Journal of Urology 154 293-298.
155. Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS & Nelson JB 2001 Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate 47 102-110.
156. Planz B, Wang Q, Kirley SD, Marberger M & McDougal WS 2001 Regulation of keratinocyte growth factor receptor and androgen receptor in epithelial cells of the human prostate. Journal of Urology 166 678-683.
157. Pollak MN, Schernhammer ES & Hankinson SE 2004 Insulin-like growth factors and neoplasia. Nature Reviews. Cancer 4 505-518.
158. Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F, Duncan RC & Lokeshwar VB 2003 Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYALl) for prostate cancer. Cancer Research 63 2638-2644.
159. Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson J, Zahn R, Riethmuller G & Pantel K 1999 Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Research 59 241-248.
160. Rao A, Woodruff RD, Wade WN, Kute TE & Cramer SD 2002 Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. Journal of Nutrition 132 3191-3194.
161. Rayford W, Noble MJ, Austenfeld MA, Weigel J, Mebust WK & Shah GV 1997 Muscarinic cholinergic receptors promote growth of human prostate cancer cells. Prostate 30 160-166.
162. Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR & Penning TM 2003 Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology 144 2922-2932.
163. Robinson EJ, Neal DE & Collins AT 1998 Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate 37 149-160.
164. Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A & Ittmann M 2000 Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Research 60 4245-4250.
165. Rumpold H, Heinrich E, Untergasser G, Hermann M, Pfister G, Plas E & Berger P 2002 Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro. Prostate 53 101-108.
166. Salnikow K, Costa M, Figg WD & Blagosklonny MV 2000 Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Research 60 5630-5634.
167. Sandhu C, Peehl DM & Slingerland J 2000 p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells. Cancer Research 60 2616-2622.
168. Schalken JA & van Leenders G 2003 Cellular and molecular biology of the prostate: stem cell biology. Urology 62 11-20.
169. Schwarze SR, Shi Y, Fu VX, Watson PA & Jarrard DF 2001 Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene 20 8184-8192.
170. Schwarze SR, DePrimo SE, Grabert LM, Fu VX, Brooks JD & Jarrard DF 2002 Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. Journal of Biological Chemistry 277 14877-14883.
171. Schwarze SR, Fu VX & Jarrard DF 2003 Cdc37 enhances proliferation and is necessary for normal human prostate epithelial cell survival. Cancer Research 63 4614-4619.
172. Shappell SB, Boeglin WE, Olson SJ, Kasper S & Brash AR 1999 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. American Journal of Pathology 155 235-245.
173. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ & Sager R 1996 Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. PNAS 93 11669-11674.
174. Sherwood ER, Berg LA, McEwan RN, Pasciak RM, Kozlowski JM & Lee C 1989 Two-dimensional protein profiles of cultured stromal and epithelial cells from hyperplastic human prostate. Journal of Cellular Biochemistry 40 201-214.
175. Shou J, Soriano R, Hayward SW, Cunha GR, Williams PM & Gao WQ 2002 Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. PNAS 99 2830-2835.
176. Signoretti S & Loda M 2001 Estrogen receptor beta in prostate cancer: brake pedal or accelerator? American Journal of Pathology 159 13-16.
177. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F & Loda M 2000 p63 is a prostate basal cell marker and is required for prostate development. American Journal of Pathology 157 1769-1775.
178. Simpson MA, Wilson CM & McCarthy JB 2002 Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. American Journal of Pathology 161 849-857.
179. Sinisi AA, Bellastella A, Prezioso D, Nicchio MR, Lotti T, Salvatore M & Pasquali D 1997 Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer. Journal of Clinical Endocrinology and Metabolism 82 2566-2569.
180. Sinisi AA, Chieffi P, Pasquali D, Kisslinger A, Staibano S, Bellastella A & Tramontano D 2002 EPN: a novel epithelial cell line derived from human prostate tissue. In Vitro Cellular and Developmental Biology. Animal 38 165-172.
181. Smitherman AB, Mohler JL, Maygarden SJ & Ornstein DK 2004 Expression of annexin I, II and VII proteins in androgen stimulated and recurrent prostate cancer. Journal of Urology 171 916-920.
182. Soda H, Raymond E, Sharma S, Lawrence R, Davidson K, Oka M, Kohno S, Izbicka E & Von Hoff DD 2000 Effects of androgens on telomerase activity in normal and malignant prostate cells in vitro. Prostate 43 161-168.
183. Solakoglu O, Maierhofer C, Lahr G, Breit E, Scheunemann P, Heumos I, Pichlmeier U, Schlimok G, Oberneder R, Kollermann MW et al. 2002 Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. PNAS 99 2246-2251.
184. Stamey TA, Caldwell MC, McNeal JE, Nolley R, Hemenez M & Downs J 2004 The PSA era in the United States is over for prostate cancer: what happened in the past 20 years? Journal of Urology 172 1297-1301.
185. Stearns ME, Hu Y & Wang M 2003a IL-10 signaling via IL-10E1 is dependent on tyrosine phosphorylation in the IL-10R alpha chain in human primary prostate cancer cell lines. Oncogens 22 3781-3791.
186. Stearns ME, Wang M, Hu Y & Garcia FU 20036 Interleukin-10 activation of the interleukin-10E1 pathway and tissue inhibitor of metalloproteinase-1 expression is enhanced by proteasome inhibitors in primary prostate tumor lines. Molecular Cancer Research 1 631-642.
187. Stearns ME, Wang M, Hu Y, Garcia FU & Rhim J 2003c Interleukin 10 blocks matrix metalloproteinase-2 and membrane type 1-matrix metalloproteinase synthesis in primary human prostate tumor lines. Clinical Cancer Research 9 1191-1199.
188. Stepanova L, Yang G, DeMayo F, Wheeler TM, Finegold M, Thompson TC & Harper JW 2000 Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene 19 2186-2193.
189. Sterling, KM Jr & Cutroneo KR 2004 Constitutive and inducible expression of cytochromes P4501A (CYP1A1 and CYP1A2) in normal prostate and prostate cancer cells. Journal of Cellular Biochemistry 91 423-429.
190. Subbarayan V, Sabichi AL, Llansa N, Lippman SM & Menter DG 2001 Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Research 61 2720-2726.
191. Sumitomo M, Asano T, Asakuma J, Nanus DM & Hayakawa M 2004 Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase. Clinical Cancer Research 10 260-266.
192. Sutkowski DM, Fong CJ, Sensibar JA, Rademaker AW, Sherwood ER, Kozlowski JM & Lee C 1992 Interaction of epidermal growth factor and transforming growth factor beta in human prostatic epithelial cells in culture. Prostate 21 133-143.
193. Takahashi S, Urano T, Tsuchiya F, Fujimura T, Kitamura T, Ouchi Y, Muramatsu M & Inoue S 2003 EBAG9/RCAS1 expression and its prognostic significance in prostatic cancer. International Journal of Cancer 106 310-315.
194. Tang DG, Li L, Chopra DP & Porter AT 1998 Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Research 58 3466-3479.
195. Tang S, Bhatia B, Maldonado CJ, Yang P, Newman RA, Liu J, Chandra D, Traag J, Klein RD, Fischer SM et al. 2002 Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. Journal of Biological Chemistry 277 16189-16201.
196. Tekur S, Lau KM, Long J, Burnstein K & Ho SM 2001 Expression of RFG/ELE1alpha/ARA70 in normal and malignant prostatic epithelial cell cultures and lines: regulation by methylation and sex steroids. Molecular Carcinogenesis 30 1-13.
197. Thebault S, Roudbaraki M, Sydorenko V, Shuba Y, Lemonnier L, Slomianny C, Dewailly E, Bonnal JL, Mauroy B, Skryma R et al. 2003 Alpha1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells. Journal of Clinical Investigation 111 1691-1701.
198. Tran CP, Lin C, Yamashiro J & Reiter RE 2002 Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Molecular Cancer Research 1 113-121.
199. Tsujimura A, Koikawa Y, Salm S, Takao T, Coetzee S, Moscatelli D, Shapiro E, Lepor H, Sun TT & Wilson EL 2002 Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. Journal of Cell Biology 157 1257-1265.
200. Udayakumar TS, Klein RD, Maliner MS, Nagle RB & Bowden GT 2001 Aberrant expression of fibroblast growth factor receptor-1 in prostate epithelial cells allows induction of promatrilysin expression by fibroblast growth factors. International Journal of Cancer 91 187-192.
201. Untergasser G, Koch HB, Menssen A & Hermeking H 2002 Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. Cancer Research 62 6255-6262.
202. Uzgare AR, Xu Y & Isaacs JT 2004 In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. Journal of Cellular Biochemistry 91 196-205.
203. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ & Lucia MS 2003 Molecular characterization of human prostate carcinoma cell lines. Prostate 57 205-225.
204. van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D & Schalken J 2000 Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Laboratory Investigation 80 1251-1258.
205. van Leenders G, van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D & Schalken J 2002 Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate 51 98-107.
206. Varani J, Hattori Y, Dame MK, Schmidt T, Murphy HS, Johnson KJ & Wojno KJ 2001 Matrix metalloproteinases (MMPs) in fresh human prostate tumour tissue and organ-cultured prostate tissue: levels of collagenolytic and gelatinolytic MMPs are low, variable and different in fresh tissue versus organ-cultured tissue. British Journal of Cancer 84 1076-1083.
207. Vtcentini C, Festuccia C, Angelucci A, Gravina GL, Muzi P, Eleuterio E, Miano R, Marronaro A, Tubaro A & Bologna M 2002 Bicalutamide dose-dependently inhibits proliferation in human prostatic carcinoma cell lines and primary cultures. Anticancer Research 22 2917-2922.
208. Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A & Bologna M 2003 Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. Journal of Cancer Research and Clinical Oncology 129 165-174.
209. Vieweg J, Boczkowski D, Roberson KM, Edwards DW, Philip M, Philip R, Rudoll T, Smith C, Robertson C & Gilboa E 1995 Efficient gene transfer with adenoassociated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Research 55 2366-2372.
210. Wallen E, Sellers RG & Peehl DM 2000 Brefeldin A induces p53-independent apoptosis in primary cultures of human prostatic cancer cells. Journal of Urology 164836-841.
211. Wang J, Torbenson M, Wang Q, Ro JY & Becich M 2003 Expression of inducible nitric oxide synthase in paired neoplastic and non-neoplastic primary prostate cell cultures and prostatectomy specimen. Urologic Oncology 21 117-122.
212. Wang S, DeGroff VL & Clinton SK 2003 Tomato and soy polyphenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. Journal of Nutrition 133 2367-2376.
213. Ware JL 1994 Prostate cancer progression. Implications of histopathology. American Journal of Pathology 145 983-993.
214. Webber MM, Bello D & Quader S 1996 Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 1. Cell markers and immortalized nontumorigenic cell lines. Prostate 29 386-394.
215. Webber MM, Bello D & Quader S 1997 Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate 30 58-64.
216. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr & Hampton GM 2001 Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Research 61 5974-5978.
217. Wilson MJ, Sellers RG, Wiehr C, Melamud O, Pei D & Peehl DM 2002 Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. Journal of Cellular Physiology 191 208-216.
218. Wu GJ, Varma VA, Wu MW, Wang SW, Qu P, Yang H, Petros JA, Lim SD & Amin MB 2001 Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues. Prostate 48 305-315.
219. Xiao D, Srivastava SK, Lew KL, Zeng Y, Hershberger P, Johnson CS, Trump DL & Singh SV 2003 Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. Carcinogenesis 24 891-897.
220. Xin H, Curry J, Johnstone RW, Nickoloff BJ & Choubey D 2003 Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence. Oncogens 22 4831-4840.
221. Xu Y, Iyengar S, Roberts RL, Shappell SB & Peehl DM 2003 Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. Journal of Cellular Physiology 196 131-143.
222. Yacoe ME, Sommer G & Peehl D 1991 In vitro proton spectroscopy of normal and abnormal prostate. Magnetic Resonance in Medicine 19 429-438.
223. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB & Nelson WG 2004 Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Research 64 1975-1986.
224. You X, Yu HM, Cohen-Gould L, Cao B, Symons M, Vande Woude GF & Knudsen BS 2003 Regulation of migration of primary prostate epithelial cells by secreted factors from prostate stromal cells. Experimental Cell Research 288 246-256.
225. Zhang J, Jung K, Lein M, Kristiansen G, Rudolph B, Hauptmann S, Schnorr D, Loening SA & Lichtinghagen R 2002 Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines. Prostate 50 38-45.
226. Zhang M, Magit D & Sager R 1997 Expression of maspin in prostate cells is regulated by a positive ets element and a negative hormonal responsive element site recognized by androgen receptor. PNAS 94 5673-5678.
227. Zhang YW & Vande Woude GF 2003 HGF/SF-met signaling in the control of branching morphogenesis and invasion. Journal of Cellular Biochemistry 88 408-417.
228. Zheng DQ, Woodard AS, Fornaro M, Tallini G & Languino LR 1999 Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Research 59 1655-1664.
229. Zhou J, Scholes J & Hsieh JT 2003 Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. Journal of Biological Chemistry 278 6936-6941.
230. Zhu X & Humphrey PA 2000 Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 56 1071-1074.